The phase III KEYNOTE-355 trial investigating Keytruda in combination with chemotherapy met one of its dual primary endpoints of progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10).
The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.
A team of scientists at the Keck School of Medicine of USC have found people who vape exhibit similar chemical modifications in their overall genome and in parts of their DNA as people who smoke cigarettes.
Fewer than half of Americans recognize that drinking alcohol, diets high in red meat, diets low in vegetables, fruits and fiber and insufficient physical activity all have a clear link to cancer development, according to the American Institute for Cancer Research's ninth Cancer Risk Awareness Survey.
In the first comparative clinical trial of lung cancer screening decision aid versus standard educational information, researchers from MD Anderson Cancer Center demonstrated that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening.
A study at MD Anderson Cancer Center showed that circulating tumor cells, a form of liquid biopsy, was independently associated with melanoma relapse, suggesting CTC assessment may be useful in identifying patients at risk for relapse who could benefit from more aggressive therapy following primary treatment.
A study analyzing new evolutionary complexity in uveal melanoma by J. William Harbour was published Jan. 24 in Nature Communications.
University of California San Diego School of Medicine researchers used genetically engineered human pluripotent stem cells to create a cancer model to study in vivo how glioblastoma develops and changes over time.
Health insurance purchased by state AIDS Drug Assistance Programs for people living with HIV in states that did not expand Medicaid are improving outcomes and have the potential to save millions in healthcare costs, a new study suggests.
The independent data monitoring committee of the phase III SANET-p study of surufatinib in advanced neuroendocrine tumors has recommended that the study end early as the pre-defined primary endpoint of progression free survival had already been met.
